These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 830747)

  • 1. C567-initiated cytolysis of lymphoid cells: description of the phenomenon and studies on its control by C567 inhibitors.
    Baker PJ; Lint TF; Mortensen RF; Gewurz H
    J Immunol; 1977 Jan; 118(1):198-202. PubMed ID: 830747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies of the inhibition of C56-initiated lysis (reactive lysis). IV. Antagonism of the inhibitory activity c567-INH by poly-L-lysine.
    McLeod B; Baker P; Behrends C; Gewurz H
    Immunology; 1975 Feb; 28(2):379-90. PubMed ID: 47309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of C56-initiated lysis by cell-bound C3 fragments: evidence for a mechanism independent of the prior binding of C56 to C3b.
    Yamamoto KI; Lint TF; Gewurz H
    J Immunol; 1977 Oct; 119(4):1346-50. PubMed ID: 894040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the complement attack mechanism in the fluid phase and its control by C567-INH: lysis of normal erythrocytes initiated by zymosan, endotoxin, and immune complexes.
    Lint TF; Behrends CL; Baker PJ; Gewurz H
    J Immunol; 1976 Nov; 117(5 Pt 1):1440-6. PubMed ID: 1002985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum lipoproteins and C567-INH activity.
    Lint TF; Behrends CL; Gewurz H
    J Immunol; 1977 Sep; 119(3):883-8. PubMed ID: 561124
    [No Abstract]   [Full Text] [Related]  

  • 6. Studies on the inhibition of C56-initiated lysis (reactive lysis). V. The roleof C567-INH in the regulation of complement-dependent haemolysis initiated by cobravenom factor.
    McLeod B; Lint TF; Baker P; Behrends C; Gewurz H
    Immunology; 1975 Apr; 28(4):741-54. PubMed ID: 1171082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of therminal components of human complement by a trypsin-activated complex of human factor B and cobra venom factor.
    Miyama A; Kato T; Minoda I; Ueda T; Kashiba S
    Jpn J Microbiol; 1976 Dec; 20(6):507-16. PubMed ID: 1035353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The properdin pathway: mechanisms of complement activation and analogies to the classical pathway.
    Fearon DT; Austen KF; Ruddy S
    Rheumatology; 1975; 6():2-16. PubMed ID: 1105744
    [No Abstract]   [Full Text] [Related]  

  • 9. Membrane attack by complement.
    Podack ER; Tschopp J
    Mol Immunol; 1984 Jul; 21(7):589-603. PubMed ID: 6379417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the mechanism of bacterial resistance to complement-mediated killing. II. C8 and C9 release C5b67 from the surface of Salmonella minnesota S218 because the terminal complex does not insert into the bacterial outer membrane.
    Joiner KA; Hammer CH; Brown EJ; Frank MM
    J Exp Med; 1982 Mar; 155(3):809-19. PubMed ID: 6801180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Complement activation and biological activities].
    Inoue K
    Nihon Saikingaku Zasshi; 1976 Jul; 31(4):535-55. PubMed ID: 988219
    [No Abstract]   [Full Text] [Related]  

  • 12. Reaction of an activated complex of guinea-pig complement components, C56, with unsensitized erythrocytes and with erythrocytes carrying C3b molecule.
    Tamura N; Baba AS
    Immunology; 1976 Jul; 31(1):151-8. PubMed ID: 1027719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deviated lysis: transfer of complement lytic activity to unsensitized cells. I. Generation of the transferable activity on the surface of complement resistant bacteria.
    Rother U; Hänsch G; Menzel J; Rother K
    Z Immunitatsforsch Exp Klin Immunol; 1974 Nov; 148(2):172-86. PubMed ID: 4283273
    [No Abstract]   [Full Text] [Related]  

  • 14. Deviated lysis: transfer of complement lytic activity to unsensitized cells. IV. Parital isolation of the activity.
    Hänsch G; Rother U; Rother K
    Z Immunitatsforsch Immunobiol; 1977 Apr; 153(1):48-59. PubMed ID: 868206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement lysis: the ultrastructure and orientation of the C5b-9 complex on target sheep erythrocyte membranes.
    Tranum-Jensen J; Bhakdi S; Bhakdi-Lehnen B; Bjerrum OJ; Speth V
    Scand J Immunol; 1978; 7(1):45-6. PubMed ID: 635472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The membrane attack mechanism of complement: photolabeling reveals insertion of terminal proteins into target membrane.
    Hu VW; Esser AF; Podack ER; Wisnieski BJ
    J Immunol; 1981 Jul; 127(1):380-6. PubMed ID: 7240749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Membrane attack complex of complement: generation of high-affinity phospholipid binding sites by fusion of five hydrophilic plasma proteins.
    Podack ER; Biesecker G; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1979 Feb; 76(2):897-901. PubMed ID: 284414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on the inhibition of C56-induced lysis (reactive lysis). VI. Modulation of C56-induced lysis polyanions and polycations.
    Baker PJ; Lint TF; McLeod BC; Behrends CL; Gewurz H
    J Immunol; 1975 Feb; 114(2 Pt 1):554-8. PubMed ID: 1168218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for a two-domain structure of the terminal membrane C5b-9 complex of human complement.
    Bhakdi S; Tranum-Jensen J
    Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5872-6. PubMed ID: 293689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical applications of complement measurements in rheumatic diseases.
    Goldstein IM
    Am J Med Sci; 1975; 269(2):172-82. PubMed ID: 1096603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.